Tower Research Capital (TRC)’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-65,203
| Closed | -$45.6K | – | 6321 |
|
|
2023
Q4 | $45.6K | Buy |
65,203
+41,160
| +171% | +$23.9K | ﹤0.01% | 3194 |
|
|
2023
Q3 | $16.6K | Buy |
24,043
+17,071
| +245% | +$21.8K | ﹤0.01% | 3550 |
|
|
2023
Q2 | $16.8K | Buy |
6,972
+3,132
| +82% | +$13.4K | ﹤0.01% | 3543 |
|
|
2023
Q1 | $31K | Buy |
3,840
+148
| +4% | +$1.97K | ﹤0.01% | 2978 |
|
|
2022
Q4 | $44K | Buy |
3,692
+1,263
| +52% | +$14.4K | ﹤0.01% | 2454 |
|
|
2022
Q3 | $34K | Sell |
2,429
-27
| -1% | -$697 | ﹤0.01% | 3505 |
|
|
2022
Q2 | $86K | Buy |
2,456
+70
| +3% | +$2.19K | ﹤0.01% | 2411 |
|
|
2022
Q1 | $95K | Buy |
2,386
+1,613
| +209% | +$69.2K | ﹤0.01% | 2243 |
|
|
2021
Q4 | $32K | Buy |
773
+46
| +6% | +$2.87K | ﹤0.01% | 3179 |
|
|
2021
Q3 | $49K | Buy |
727
+344
| +90% | +$25.2K | ﹤0.01% | 2986 |
|
|
2021
Q2 | $29K | Buy |
383
+254
| +197% | +$15.5K | ﹤0.01% | 3547 |
|
|
2021
Q1 | $9K | Sell |
129
-39
| -23% | -$3.04K | ﹤0.01% | 4443 |
|
|
2020
Q4 | $6K | Buy |
+168
| New | +$7.47K | ﹤0.01% | 4577 |
|
|
2020
Q3 | – | Sell |
-511
| Closed | -$19K | – | 5185 |
|
|
2020
Q2 | $19K | Buy |
+511
| New | +$17.5K | ﹤0.01% | 3716 |
|
|
2019
Q3 | – | Sell |
-13
| Closed | -$1K | – | 4632 |
|
|
2019
Q2 | $1K | Buy |
+13
| New | +$1.58K | ﹤0.01% | 3518 |
|
|
2016
Q4 | – | Sell |
-14
| Closed | -$3K | – | 4533 |
|
|
2016
Q3 | $3K | Buy |
+14
| New | +$2.91K | ﹤0.01% | 2926 |
|
|
2016
Q2 | – | Sell |
-4
| Closed | -$2K | – | 5119 |
|
|
2016
Q1 | $2K | Buy |
+4
| New | +$1.43K | ﹤0.01% | 3475 |
|
|
2015
Q4 | – | Sell |
-28
| Closed | -$7K | – | 5195 |
|
|
2015
Q3 | $7K | Buy |
28
+23
| +460% | +$6.41K | ﹤0.01% | 2586 |
|
|
2015
Q2 | $2K | Buy |
+5
| New | +$1.51K | ﹤0.01% | 3814 |
|
|
2014
Q3 | – | Sell |
-1
| Closed | – | – | 4998 |
|
|
2014
Q2 | $0 | Buy |
+1
| New | +$393 | ﹤0.01% | 4760 |
|
|
2014
Q1 | – | Sell |
-3
| Closed | -$1.36K | – | 5054 |
|
|
2013
Q4 | $1K | Buy |
+3
| New | +$1.31K | ﹤0.01% | 4276 |
|
Other funds holding DMK
Tower Research Capital (TRC)'s DMK Position: Q1 2024 in Review
Tower Research Capital (TRC) sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 65,203 shares — an estimated $45.6K sold.
Tower Research Capital (TRC) first reported a position in DMK in Q4 2013 and held it in 21 quarters. The position peaked at $95K in Q1 2022. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.
- Tower Research Capital (TRC) reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 65,203 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $45.6K.
- Tower Research Capital (TRC) first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 21 quarters.
- Tower Research Capital (TRC)'s DMK Pharmaceuticals Corporation Common Stock position peaked at $95K in Q1 2022.
- 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.